BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1434@pharmaconomics
DTSTAMP:20260707T020020Z
DTSTART;VALUE=DATE:20260401
DTEND;VALUE=DATE:20260402
SUMMARY:SNY PDUFA — Dupixent
DESCRIPTION:The FDA's approval decision on Dupixent for chronic spontaneous urticaria is due Apr 1\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1121404/000119312526086540/d28705dex993.htm\n\nTrack it: https://pharmaconomics.com/e/1434
URL:https://pharmaconomics.com/e/1434
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:SNY catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR